TD Asset Management Inc Has $4.10 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

TD Asset Management Inc lowered its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 35.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,690 shares of the company’s stock after selling 65,200 shares during the period. TD Asset Management Inc owned about 0.15% of IDEAYA Biosciences worth $4,097,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Ameritas Investment Partners Inc. boosted its stake in IDEAYA Biosciences by 5.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company’s stock worth $288,000 after buying an additional 332 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of IDEAYA Biosciences by 4.4% in the 1st quarter. Principal Financial Group Inc. now owns 15,275 shares of the company’s stock valued at $670,000 after purchasing an additional 648 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of IDEAYA Biosciences by 38.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock valued at $117,000 after purchasing an additional 927 shares in the last quarter. Covestor Ltd boosted its stake in shares of IDEAYA Biosciences by 9,225.0% in the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock valued at $49,000 after purchasing an additional 1,107 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of IDEAYA Biosciences by 4.9% in the 4th quarter. Franklin Resources Inc. now owns 27,237 shares of the company’s stock valued at $969,000 after purchasing an additional 1,260 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. reduced their target price on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. BTIG Research boosted their target price on shares of IDEAYA Biosciences from $55.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, August 7th. Lifesci Capital upgraded shares of IDEAYA Biosciences to a “strong-buy” rating in a research note on Monday, July 29th. Finally, Mizuho started coverage on IDEAYA Biosciences in a report on Monday, July 8th. They issued an “outperform” rating and a $50.00 price target for the company. Twelve research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $56.20.

IDEAYA Biosciences Trading Down 1.2 %

Shares of NASDAQ:IDYA opened at $36.20 on Thursday. The stock has a market capitalization of $3.06 billion, a P/E ratio of -18.01 and a beta of 0.84. IDEAYA Biosciences, Inc. has a 1-year low of $23.41 and a 1-year high of $47.74. The business has a 50-day moving average price of $39.14 and a two-hundred day moving average price of $40.18.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.14). IDEAYA Biosciences had a negative return on equity of 20.52% and a negative net margin of 483.05%. During the same period in the prior year, the firm earned ($0.50) EPS. As a group, equities analysts predict that IDEAYA Biosciences, Inc. will post -2.51 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.